Status:
RECRUITING
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
Lead Sponsor:
Northwestern University
Conditions:
Lactation Suppressed
Second Trimester Abortion
Eligibility:
FEMALE
18-50 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks ...
Eligibility Criteria
Inclusion
- pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises
- ages 18 to 50
- con provide informed consent in English
Exclusion
- Age under 18 or above 50
- gestational ages before 16 weeks 0 days or after 20 weeks 0 days
- unable to provide written consent in English
- hypertensive disorder
- uncontrolled hypertension or known hypersensitivity to ergot derivatives
- History of cardiac valvular disorders
- history of pulmonary fibrosis
- documented bipolar schizophrenia
- documented allergy to medication, including lactose intolerance (placebo pill involves lactose)
Key Trial Info
Start Date :
December 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06123026
Start Date
December 18 2023
End Date
June 30 2024
Last Update
May 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Medical Center
Chicago, Illinois, United States, 60611